AstraZeneca Plc (NYSE:AZN - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $180.13 and traded as low as $178.29. AstraZeneca shares last traded at $178.7850, with a volume of 2,537,790 shares changing hands.
Wall Street Analyst Weigh In
Several analysts have issued reports on the stock. Nordea Equity Research raised shares of AstraZeneca from a "sell" rating to a "buy" rating in a research note on Tuesday, October 13th. Wall Street Zen raised AstraZeneca from a "hold" rating to a "buy" rating in a research note on Saturday, October 31st. CICC Research started coverage on AstraZeneca in a report on Sunday, August 23rd. They set an "outperform" rating and a $198.00 price objective for the company. Deutsche Bank raised AstraZeneca from a "sell" rating to a "hold" rating in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada started coverage on AstraZeneca in a research note on Tuesday, September 8th. They issued an "outperform" rating on the stock. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, AstraZeneca has an average rating of "Moderate Buy" and a consensus price target of $206.67.
Check Out Our Latest Stock Report on AZN
AstraZeneca Stock Performance
The company has a quick ratio of 0.79, a current ratio of 1.01 and a debt-to-equity ratio of 0.51. The firm has a 50 day moving average price of $170.12 and a 200 day moving average price of $180.13. The stock has a market cap of $277.28 billion, a PE ratio of 25.29, a price-to-earnings-growth ratio of 1.41 and a beta of 0.24.
AstraZeneca (NYSE:AZN - Get Free Report) last posted its quarterly earnings results on Saturday, October 31st. The company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.60 by $0.19. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The business had revenue of $16.21 billion during the quarter, compared to analyst estimates of $16 billion. During the same quarter in the previous year, the business posted $2.38 EPS. The company's quarterly revenue was up 6.5% compared to the same quarter last year. As a group, research analysts forecast that AstraZeneca Plc will post 10.22 earnings per share for the current year.
Institutional Trading of AstraZeneca
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. McIlrath & Eck LLC lifted its holdings in shares of AstraZeneca by 443.3% in the 3rd quarter. McIlrath & Eck LLC now owns 163 shares of the company's stock valued at $27,000 after buying an additional 133 shares during the period. Roxbury Financial LLC acquired a new stake in shares of AstraZeneca in the second quarter valued at about $29,000. Laurel Wealth Advisors LLC purchased a new stake in AstraZeneca during the 3rd quarter worth approximately $30,000. GK Wealth Management LLC purchased a new stake in shares of AstraZeneca during the third quarter worth approximately $31,000. Finally, Lynch Investment Planning LLC purchased a new stake in AstraZeneca during the 3rd quarter valued at about $32,000. Institutional investors own 20.35% of the company's stock.
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.